The Application of Glucose CEST MR Imaging in Brain Tumor

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-06-01

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recently, natural D-glucose was suggested as a potential biodegradable contrast agent. The feasibility of using D-glucose for dynamic perfusion imaging was explored to detect malignant brain tumors based on blood brain barrier breakdown. Our study try to evaluate the feasibility of dynamic glucose enhanced(DGE) magnetic resonance imaging（MRI）in brain tumor, which based on D-glucose weighted chemical exchange saturation transfer (gluceoCEST).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study on Neuroepithelial Tumor Grading and Pseudoprogression After Glioma Therapy Using Advanced Functional MRI Techniques

NCT02622620

Glioma Neoplasms

UNKNOWN

The Predictive Value of MRI for Adult-type Diffuse Gliomas

NCT06572592

Glioma

NOT_YET_RECRUITING

Histopathologic Evaluation of High Grade Brain Tumors by High Order Diffusion Tensor Imaging

NCT01699269

High Grade Brain Tumor

COMPLETED NA

MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases

NCT04246879

Brain Metastases

ACTIVE_NOT_RECRUITING NA

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

NCT04540107

Recurrent World Health Organization (WHO) Grade II Glioma Recurrent WHO Grade III Glioma WHO Grade II Glioma +1 more

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

methods： Brain tumor patients were recruited. Time-resolved glucose signal changes were detected using chemical exchange saturation transfer (glucoCEST) MRI. Dynamic glucose enhanced (DGE) MRI was used to measure tissue response to an intravenous bolus of D-glucose. During the dynamic glucose scan, a brief hyperglycemic state was established by intravenous infusion of hospital-grade D50 glucose (D50, 25 g of dextrose in 50 mL of water sterile solution), followed by 20 mL of saline solution in 1 arm. The glucose infusion was performed using a power injector at an infusion rate of 0.2 mL/s, corresponding to total infusion times of 250 seconds. Performing contrast enhancement based on Gd-DTPA in 30 minutes later, which was used for comparison as golden standard.

The area of hyperintensity will be measured, which represents the area of brain tumor.

Differential test and Consistency analysis were used for statistical analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Magnetic Resonance Imaging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

D-glucose

During the dynamic glucose scan, a brief hyperglycemic state was established by intravenous infusion of hospital-grade D50 glucose (D50, 25 g of dextrose in 50 mL of water sterile solution), followed by 20 mL of saline solution in 1 arm. The glucose infusion was performed using a power injector at an infusion rate of 0.2 mL/s, corresponding to total infusion times 250 seconds.

Group Type OTHER

d-glucose

Intervention Type DRUG

using d-glucose as an contrast agent on CEST MR Imaging

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

d-glucose

using d-glucose as an contrast agent on CEST MR Imaging

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

50% dextrose injection

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient must have a brain mass consistent with a primary brain tumor or metastatic brain tumor
* able to give consent and willingness to participate in this study.

Exclusion Criteria

* presence of any ferromagnetic implant (cardiac pacemakers, aneurysm clip, etc.)
* pregnancy
* claustrophobia or anxiety disorder
* history of vertigo
* persons with diabetes mellitus (self-report or HbA1C \>= 6.5%)
* Sickle cell disease
* persons taking prescription medicine for hypertension
* blood iron deficiency (Hb concentration \< 11 g/dL or Hct \< 32%)
* If volunteering for MRI: history of kidney disease and/or eGFR \< 60.
* Middle-ear disorder
* double vision
* Seizure disorder
* Multiple myeloma
* Solid organ transplant
* History of severe hepatic disease/liver transplant/pending liver transplant

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No